How GLP-1 medications work for weight loss

GLP-1 (glucagon-like peptide-1) is a hormone your intestines release after eating. It signals fullness to your brain, slows how quickly your stomach empties, and helps regulate insulin. GLP-1 receptor agonist medications — such as semaglutide and tirzepatide — mimic this hormone at higher, longer-lasting levels than the body produces naturally.

The practical effect most patients notice first is a quieter relationship with food: smaller portions feel satisfying, cravings soften, and the constant background 'food noise' fades. Because the stomach empties more slowly, fullness lasts longer between meals.

In clinical trials, adults taking semaglutide lost an average of about 15% of their body weight over 68 weeks, and tirzepatide trials have shown average losses around 20% at the highest doses — in both cases alongside diet and exercise changes, compared with roughly 2–3% from lifestyle changes alone.

GLP-1 therapy is not appropriate for everyone. People with a personal or family history of medullary thyroid carcinoma or MEN 2 should not take these medications, and common side effects include nausea and constipation, particularly during dose increases. That is why a licensed provider reviews your full health history before prescribing, and why dose titration is managed gradually.

If you are considering GLP-1 therapy, the best first step is a structured intake with a licensed provider who can evaluate whether treatment fits your health profile and goals.